Table 2.
Ref.
|
Year
|
HbA1c (%), mean ± SD
|
Type of study
|
Intervention
|
Sample size
|
Main findings
|
Razavi et al[43] | 2021 | Fasting glucose > 126 mg/dL | Multiethnic cohort | Two CAC scans with a 10-yr interval | 574 | More than 40% of adults with MetS or T2DM and baseline CAC = 0 had long-term absence of CAC |
Schindler et al[34] | 2009 | 9.8 ± 2.7 | Prospective | Glyburide 10-20 mg/d ± metformin 500-1000 mg/d; Observation for 14 ± 2 mo | 39 | Lower progression of cIMT and CAC with glucose-lowering treatment |
Won et al[38] | 2018 | 7.5 ± 1.2 and 6.4 ± 0.9 | Retrospective, single-ethnicity, multicenter observational | Data on the impact of optimal glycemic control on CAC progression | 1637 | Attenuation of CAC progression, especially if CAC > 400 |
Funck et al[41] | 2017 | 6.5 ± 0.7 | Prospective cohort | Observational, 5-yr follow-up | 106 | CAC progression in DM compared to healthy. Independently associated with PWV |
Malik et al[42] | 2017 | HbA1c measurements were not available at baseline | Prospective cohort | Observational | 6814 | Baseline CAC values most important progression determinant |
CAC: Coronary artery calcification; cIMT: Carotid intima media thickness; DM: Diabetes mellitus; MetS: Metabolic syndrome; PWV: Pulse wave velocity; SD: Standard deviation; T2DM: Type 2 diabetes mellitus.